Zulu
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Imikhiqizo Izigaba
Imikhiqizo efakiwe
Amathebulethi eLenopril Anika Amandla Ukulawula Umfutho Wegazi kanye Nempilo Yenhliziyo

Amathebulethi eLenopril Anika Amandla Ukulawula Umfutho Wegazi kanye Nempilo Yenhliziyo
I-Telmisartan I-antihypertensive Protecting renal engcono

I-Telmisartan I-antihypertensive Protecting renal engcono
I-Flumazenil I-GABAA Receptor Antagonist ekhethiwe kanye nezicelo zayo zokwelapha

I-Flumazenil I-GABAA Receptor Antagonist ekhethiwe kanye nezicelo zayo zokwelapha
I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

I-Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers

I-Dabrafenib I-Targeted Therapy ye-BRAF-Mutated Cancers
I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control

I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control
I-Cisapride Gastric Stimulant for Indigestion and Digestive Disorders

I-Cisapride Gastric Stimulant for Indigestion and Digestive Disorders
I-YK-11 I-SARM Enamandla Yokwakhiwa Kwemisipha, Ukuzuza Amandla, kanye Ne-Myostatin Inhibition

I-YK-11 I-SARM Enamandla Yokwakhiwa Kwemisipha, Ukuzuza Amandla, kanye Ne-Myostatin Inhibition
I-Ostarine (MK-2866) I-SARM Eguquguqukayo Yokukhula Kwemisipha, Ukulahlekelwa Kwamafutha, Nokubuyiswa Komzimba

I-Ostarine (MK-2866) I-SARM Eguquguqukayo Yokukhula Kwemisipha, Ukulahlekelwa Kwamafutha, Nokubuyiswa Komzimba
I-MK-677 Inhlanganisela Eyingqayizivele Yokukhula Kwemisipha, Ukukhuthazela, Nokubuyiselwa

I-MK-677 Inhlanganisela Eyingqayizivele Yokukhula Kwemisipha, Ukukhuthazela, Nokubuyiselwa
0102030405
I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control
I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control
I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control
I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control

I-Tirzepatide Dual GLP-1 kanye ne-GIP Receptor Agonist for Weight Management and Glycemic Control

Intengo yesithenjwa:USD 300-600/g

  • Igama Lomkhiqizo I-Tirzepatide
  • Inombolo ye-CAS. 2023788-19-2
  • MF I-C225H348N48O68
  • MW 4813.45
Xhumana nathi
imininingwane yomkhiqizo

Incazelo Eningiliziwe

I-Tirzepatide umuthi wenoveli osetshenziselwa ukuphatha isisindo eside ezigulini ezikhuluphele ngokukhuluphala kwabantu abadala noma i-comorbidities ehlobene nesisindo. Kuyi-agonist ethembele ku-glucose ye-glucagon polypeptide (GIP) kanye ne-glucagon-like peptide-1 (GLP-1) receptors. Igunyazwe yi-FDA ngo-2022, i-tirzepatide ihlanganisa imiphumela yama-enteric proinsulins abe yi-molecule eyodwa, ithuthukisa ukukhiqizwa kwe-insulin futhi yehlise namazinga eglucagon. Le ndatshana ihlola indlela yokusebenza, ukusebenza kahle komtholampilo, kanye nephrofayili yokuphepha ye-tirzepatide njengendlela yokwelapha ehambisanayo yokwehlisa isisindo kanye nokulawulwa okuthuthukisiwe kwe-glycemic ezigulini ezinesifo sikashukela sohlobo 2.

I. Ukuqonda i-Tirzepatide:
A. I-agonist ethembele ku-Glucose ye-GIP nama-GLP-1 receptors
B. Indlela yokusebenza: ukuthuthukiswa kwesigaba I kanye nesigaba II sokuphuma kwe-insulin, ukwehlisa amazinga eglucagon

II. Ukusetshenziswa Kwezokwelapha kanye Nemvume ye-FDA:
A. Inkomba: Ukulawulwa kwesisindo sesikhathi eside ezigulini ezikhuluphele ngokukhuluphala kwabantu abadala noma okuhambisana nesisindo
B. I-Adjunctive therapy yokuthuthukisa ukulawulwa kwe-glycemic kubantu abadala abanesifo sikashukela sohlobo lwe-2
Imvume ye-C. FDA kanye nokumaketha ngu-Eli Lilly ngo-2022

1715863859091roe

III. Ukusebenza kahle ekulawuleni isisindo:

A. Ukusebenza kokuqhathanisa:

Iphesenti lokuncipha kwesisindo: Idosi ephansi (5mg), umthamo omaphakathi (10mg), kanye nedosi ephezulu (15mg) amaqembu

Isilinganiso samaphesenti okuncipha kwesisindo emaqenjini emithamo ahlukene

Ukuqhathanisa neqembu le-placebo

Iphesenti lezifundo ezithola ukuncipha kwesisindo ngaphezu kuka-20%

B. Iphrofayela yokuphepha: Imvamisa yokusabela okubi uma kuqhathaniswa neqembu le-placebo

C. Ukuqhathanisa neminye imithi yokwehlisa isisindo:

I-Orlistat (i-over-the-counter): Umehluko kumaphesenti wokulahlekelwa kwesisindo


IV. Indlela Yokulawula I-Glycemic Nokuncipha Kwesisindo:

A. Ukwenza kusebenze ama-GLP-1 nama-GIP receptors

B. Ukunciphisa isifiso sokudla kanye nokunciphisa ukudla okudlayo



17158639023143ie


I-Tirzepatide, njenge-GLP-1 ekabili kanye ne-GIP receptor agonist, ihlinzeka ngokuphathwa okusebenzayo kwesisindo nokulawulwa okuthuthukisiwe kwe-glycemic ezigulini ezikhuluphele ngokukhuluphala ngokweqile noma ezihambisana nesisindo esihlobene nesisindo, kanye nakubantu abanesifo sikashukela sohlobo 2. Indlela yayo yokusebenza encike ku-glucose ithuthukisa ukukhiqizwa kwe-insulin futhi yehlise namazinga e-glucagon. Ngamaphesenti abalulekile okwehla kwesisindo kanye nephrofayili yokuphepha evumayo, i-tirzepatide igqama njengomuthi onamandla wokulawula isisindo isikhathi eside. Ucwaningo olwengeziwe kanye nezifundo zomtholampilo zizoqhubeka nokuhlola izinzuzo ezingaba khona kanye nokusetshenziswa kwalo muthi othembisayo.
Ukuze sinikeze isipiliyoni sokuhweba esingcono, singakwazi ukwenza ngokwezifiso i-capsule nemikhiqizo yoketshezi, ngokuya ngezidingo zakho zezithako.
Singakwazi ukwenza ngokwezifiso umthamo: 500mg/capsule, 550mg/capsule, 600mg/capsule.
Singakwazi ukwenza ngokwezifiso ukupakishwa: 60 caps / ibhodlela, 90 caps / ibhodlela, 120 caps / ibhodlela.
Singakwazi ukwenza ngokwezifiso amagobolondo we-capsule nemibala: amagobolondo e-capsule yezitshalo, amagobolondo we-gelatin capsule.

Ukucaciswa

1715845381118yxs